# PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

> **NCT04174339** · NA · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Gastric Adenocarcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib Mesylate
- **DRUG:** POF

## Key facts

- **NCT ID:** NCT04174339
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-10
- **Primary completion:** 2020-12-09
- **Final completion:** 2021-05-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04174339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04174339, "PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04174339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*